Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad
Journal of Cystic Fibrosis · 2026-01 · 25 (1) · 28-31
DOI: 10.1016/j.jcf.2025.11.013 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Cystic Fibrosis, 2026-01. Verfasst von Rachel G Sinkey und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, University of Alabama at Birmingham, 1700 Sixth Avenue S Suite 10270, Birmingham, AL 35233, USA. Electronic ad…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Fetal Blood, Milk, Human. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NICHD NIH HHS, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
There are a paucity of data regarding the pharmacokinetics (PK) of elexacaftor (ELX)/tezacaftor(TEZ)/ivacaftor(IVA)(ETI) in pregnant and/or lactating mothers and their offspring. We conducted a PK assessment of ETI and their metabolites in maternal/neonatal/cord blood and breast milk from a cystic fibrosis (CF) carrier mother/affected fetus dyad, collecting specimens at delivery, 1 and 4 weeks after birth. The infant received on-label direct dosing after 1 month of life; all PK samples were collected prior to initiation of neonatal dosing and analyzed using LC-MS/MS. Measured metabolites were IVA-M1, IVA-M6, ELX-M23 and TEZ-M1. The female infant was born at 37 weeks gestation with successful meconium passage on the first day of life. Sweat chloride at 15 days (16 and 17 mmol/L) and immunoreactive trypsinogen (27.5 ng/mL) were normal. Neonatal genetics confirmed F508del/P67L genotype. Parent drug concentrations were measurable in cord blood and capillary heel sticks, indicating they cross the placenta. After delivery, the infant's only source of modulators was via breast milk. Breast milk concentrations were measured at 1 and 4 weeks of life. Relative to maternal concentrations, ETI and their metabolites were present at lower concentrations. Heel stick specimens revealed undetectable IVA, but ELX and TEZ were below the assay limit. IVA-M1 and IV-M6 concentrations were lower at 1 and 4 weeks relative to delivery. To our knowledge, this is the first report of ETI metabolite concentrations following in utero administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics & Gynecology, University of Alabama at Birmingham, 1700 Sixth Avenue S Suite 10270, Birmingham, AL 35233, USA. Electronic address: rsinkey@uabmc.edu.
- Division of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, 2000 Sixth Avenue S, Birmingham, AL 35233, USA. Electronic address: bgarcia@uab.edu.
- Division of Pediatric Pulmonary & Sleep Medicine, University of Alabama at Birmingham, 1600 Seventh Avenue S, Birmingham, AL 35233, USA. Electronic address: cmfowler@uabmc.edu.
- Division of Pulmonary, Allergy, & Critical Care Medicine, University of Alabama at Birmingham, 2000 Sixth Avenue S, Birmingham, AL 35233, USA. Electronic address: skrick@uabmc.edu.
- Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35233, USA.
- Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, 1670 University Boulevard, Birmingham, AL 35233, USA. Electronic address: eacosta@uab.edu.
Förderung
- NHLBI NIH HHS
- NICHD NIH HHS
- Cystic Fibrosis Foundation
- The University of Alabama at Birmingham Department of Medicine
- Universitat Autònoma de Barcelona
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- National Heart Lung and Blood Institute
Zitieren
APA
Sinkey, R. G., Garcia, B., Fowler, C. M., Krick, S., Ryan, K. J., Acosta, E. P., & Guimbellot, J. S. (2026). Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. Journal of Cystic Fibrosis, 25(1), 28-31. https://doi.org/10.1016/j.jcf.2025.11.013
Vancouver
Sinkey RG, Garcia B, Fowler CM, Krick S, Ryan KJ, Acosta EP, et al. Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad. Journal of Cystic Fibrosis. 2026;25(1):28-31. doi:10.1016/j.jcf.2025.11.013
BibTeX
@article{Sinkey2026,
author = {Sinkey, Rachel G and Garcia, Bryan and Fowler, Christopher Miles and Krick, Stefanie and Ryan, Kevin J and Acosta, Edward P and Guimbellot, Jennifer S},
title = {Pharmacokinetic assessment of elexacaftor/tezacaftor/ivacaftor and their metabolites in maternal blood, cord blood, the neonate, and breastmilk of a cystic fibrosis carrier mother/affected fetus dyad},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {1},
pages = {28--31},
doi = {10.1016/j.jcf.2025.11.013}
}
EUVIMED